Worcester, United Kingdom – 19 May 2026
Building on its recent €3.5M seed round, Garland Surgical launches preparations for a larger Series A financing, supported by specialist life sciences investment bank Ferghana Partners (New York, California, London) to fund clinical studies and subsequently unlock commercialisation of its patented TriActiv Hip™ system (previously known as MaltaHip).
Garland Surgical Ltd, a UK‑based orthopaedic medical device company developing the TriActiv Hip, today announced the successful close of its €3.5 million seed funding round. The round combines €2.1 million in equity financing, with up to €1.4 million in non‑dilutive grant funding from Malta Enterprise, to support ongoing product development, regulatory preparation, and early clinical activities.
Building on this momentum, Garland is now launching its Series A financing, supported by Ferghana Partners who have a track record of delivering high quality, senior level advice to the life sciences sector for value-added corporate partnering, M&A (acquisitions and divestments) and creative financing transactions. This next round of investment is intended to prepare the Company to make regulatory submissions for FDA and MDR clearance, to fund clinical studies, and to unlock the commercial potential of the TriActiv Hip across key global markets: these activities reflect Garland’s ambition to redefine and innovate the standard of care in total hip replacement.
Garland is focused on providing a novel, practical total hip replacement solution through its TriActiv Hip, a patented, next‑generation triaxial hip system designed first and foremost to deliver a wider and more natural range of motion, while also providing exceptional stability and ultra‑low wear compared to conventional ball‑and‑socket implants. Evolved from the MaltaHip project, TriActiv Hip aims to offer a long‑lasting solution for both high‑demand and high‑risk patients, including those prone to dislocation and instability, addressing the real‑world expectations of today’s diverse and increasingly active patient population. By targeting mobility, stability and durability in a single platform, Garland is positioning TriActiv Hip to disrupt an $8 billion mature market that has not been optimised for modern longevity, activity levels, and instability risk.
Closing this seed round is a pivotal milestone in our journey to deliver a true ‘hip for life’,” said Simon Mifsud, Co‑founder and CEO of Garland. “The confidence shown by our investors and collaborators enables the company not only to complete development of the TriActiv Hip platform and move towards regulatory submissions in the EU and USA, but also to launch our Series A financing in partnership with Ferghana Partners. We intend to progress towards first‑in‑human clinical studies and commercial preparation that can transform outcomes for patients worldwide.”
“One of the biggest shifts in hip replacement is recognising that different patients need different solutions, particularly around instability risk,” said Consultant Orthopaedic Surgeon Professor Ed Davis from the Royal Orthopaedic Hospital, Birmingham, UK. “While dual mobility has helped address this problem, it is not a perfect solution, and more ‘constrained design’ options bring their own challenges. The TriActiv Hip has the potential to offer stability in a more balanced way, better aligned to the needs of higher-risk and active patients.”
“Conventional hip replacements were not previously optimised for today’s requirements of longevity, stability and activity levels,” added John Shapland, Chief Technology Officer at Garland. “Patients want a hip that feels natural, stays stable and lasts for decades, and our triaxial design targets these demands head‑on, as it combines enhanced stability, a wider range of motion and ultra‑low wear characteristics intended to support a lifetime of performance. Compatible with the majority of femoral stems and using standard surgical technique, Garland has designed TriActiv Hip to offer clinicians a versatile, innovative solution for this higher-risk and demanding patient population.”
The seed financing will be used (1) to complete final design and verification of the TriActiv Hip system in line with regulatory requirements and (2) to strengthen quality and regulatory infrastructure in preparation for EU and US regulatory submissions. Garland will also invest in team development, surgeon engagement, usability work, and planning of first‑in‑human clinical trials to support its evidence‑generation roadmap.
As it launches preparations for the Series A, Garland plans a two‑stage structure supported by Ferghana Partners, with an initial A1 tranche focused on regulatory clearance preparation and its submissions for FDA and MDR review, followed by an A2 tranche to support clinical trials and market entry. Together, these financings are designed to take TriActiv Hip from late‑stage development through clinical validation and into early commercialisation in priority markets.
Total hip replacement has seen incremental improvement over decades, but most implants still follow a conventional ball‑and‑socket blueprint that was not designed for today’s life expectancy, activity patterns, and case complexity. TriActiv Hip introduces a fundamentally different triaxial architecture that is engineered to unlock a wider, more natural movement envelope while maintaining control throughout the range of motion. By reshaping how physical forces are transmitted and constrained in the joint, the TriActiv system is intended to cut the risk of dislocation, reduce edge‑loading and wear, and support long‑term mechanical integrity. This combination of motion, control and durability is designed to change how surgeons think about primary and complex hip replacement, to expand treatment options for higher‑risk and higher‑demand patients, and to create a new benchmark for lifetime hip performance.
About Garland Surgical
Garland Surgical Ltd is a medical device design and development company headquartered near Worcester, United Kingdom, with operations in Malta and collaborations across Europe. Founded in 2022, the Company’s mission is to redefine total hip replacement through an innovative, next‑generation design that delivers exceptional mobility, stability, and lasting durability. Bringing together engineering excellence, expert clinical collaboration, and a world‑class team, Garland Surgical is creating implants that reflect the realities of today’s diverse, demanding, active patients for whom it aims to transform surgical outcomes, empowering them to move freely and live fully.
Media and investor contact:
Simon Mifsud CEO, Garland Surgical Ltd
